Skip to main content

Week In Review: Abpro Bio Signs $1.1 Billion Deal For China-Asian Rights To Two Bi-Specifics

Abpro Bio, a Korean company, announced a $1.1 billion agreement to acquire Asian rights (including China) to two bispecific antibody candidates being developed by Abpro of Boston.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.